ResultsIQ

ResultsIQ › Latest results › Aster DM Quality Care Limited

Aster DM Quality Care Limited Q1 FY26 earnings call summary

NSE: ASTERDM · BSE: 540975

Earnings call of 31 Jul 2025, summarised by AI from the filing.

Mid-teen revenue growth over 3-4 years, with 7-8% from volume and 7-8% from ARPOB.

Key takeaways

  1. Guidance Mid-teen revenue growth over 3-4 years, with 7-8% from volume and 7-8% from ARPOB.
  2. Kerala recovery Kerala revenue grew 5% year-on-year after 4% decline in Q4 FY25, driven by 6% sequential volume increase.
  3. Risk Andhra and Telangana EBITDA margin dipped due to higher material costs and clinical talent attrition.

Original filing on BSE

Aster DM Quality Care Limited Q1 FY27 results

As filed: Revenue ₹1,311 cr (+22% year on year), EBITDA ₹264 cr (+28% year on year), PAT ₹29.3 cr (+38% year on year), EBITDA margin 20.2% (+96 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹1,182 cr (+18% year on year), EBITDA ₹233 cr (+21% year on year), PAT ₹154 cr (+79% year on year), EBITDA margin 19.7% (+47 bps). Score 48 of 100, In line with trend. Revenue, EBITDA and profit growth were above the company's own trend. EBITDA margin rose 47 bps year on year. Tax rate 6%. Consolidated profit +79% but standalone -55%. Share price after the results: +3.9% in 29 days (Nifty 500: −0.1%).
  • Q3 FY26: Revenue ₹1,186 cr (+13% year on year), EBITDA ₹211 cr (+12% year on year), PAT ₹58.7 cr (+9% year on year), EBITDA margin 17.8% (−18 bps). Score 36 of 100, Below trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it; profit before exceptional items growth was below it. EBITDA margin fell 18 bps year on year. Other income 25% of PBT. Tax rate 40%. Profit fell 23% from last quarter. Share price after the results: +14.8% in 28 days (Nifty 500: +0.4%).
  • Q2 FY26: Revenue ₹1,197 cr (+10% year on year), EBITDA ₹250 cr (+14% year on year), PAT ₹121 cr (+14% year on year), EBITDA margin 20.9% (+72 bps). Score 51 of 100, In line with trend. Revenue and profit growth were in line with the company's own trend; EBITDA growth was above it. EBITDA margin rose 72 bps year on year. Share price after the results: −7.6% in 29 days (Nifty 500: +1.4%).
  • Q1 FY26: Revenue ₹1,078 cr (+8% year on year), EBITDA ₹207 cr (+27% year on year), PAT ₹94.0 cr (−98% year on year), EBITDA margin 19.2% (+293 bps). Score 50 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA growth was above it; profit growth was below it. EBITDA margin rose 293 bps year on year. Share price after the results: +1.4% in 30 days (Nifty 500: −2.5%).
  • Q4 FY25: Revenue ₹1,000 cr (+3% year on year), EBITDA ₹192 cr (+21% year on year), PAT ₹86.0 cr (+69% year on year), EBITDA margin 19.2% (+288 bps). Score 43 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA and profit before exceptional items growth were above it. EBITDA margin rose 288 bps year on year. Other income 31% of PBT. Tax rate 5%. Revenue fell 5% from last quarter. Share price after the results: +1.4% in 30 days (Nifty 500: +1.4%).
  • Q3 FY25: Revenue ₹1,050 cr (−72% year on year), EBITDA ₹189 cr (−67% year on year), PAT ₹64.0 cr (−47% year on year), EBITDA margin 18.0% (+277 bps). Score 11 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit before exceptional items growth was below it. EBITDA margin rose 277 bps year on year. Other income 31% of PBT. Tax rate 36%. Revenue fell 3% from last quarter.
  • Q2 FY25: Revenue ₹1,086 cr (−67% year on year), EBITDA ₹219 cr (−42% year on year), PAT ₹106 cr, EBITDA margin 20.2% (+880 bps). Score 21 of 100, Below trend. EBITDA margin rose 880 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 98% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Aster DM Quality Care Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.